Therapeutics announced additional preliminary clinical data from cohort 3 of an investigator-initiated Phase 1b clinical trial of GR-MD-02 used in combination with Keytruda in patients with metastatic melanoma for which Keytruda is indicated or those patients whose melanoma progressed during or recently after Keytruda monotherapy.
The effects of intracellular galectin
can be approached either by experimenting with Gal-3-deficient cells from KO mice or by silencing Gal-3 expression in human cells.
Shlevin, Ph.D., President and Chief Executive Officer of Galectin
Therapeutics, said, "Over the past several months we have made significant progress advancing our proprietary compound, belapectin for a Phase 3 trial.
Release date- 05082019 - Galectin
Therapeutics Inc.(NASDAQ: GALT), the leading developer of therapeutics that target galectin
proteins, today announced it has submitted for assessment the Phase 3 protocol for using belapectin (GR-MD-02) for the treatment of compensated non-alcoholic steatohepatitis (NASH) cirrhosis without esophageal varices (the NASH-RX trial).
The chimera type, including galectin
3, which consists of unusual tandem repeats of proline- and glycine-rich short stretches fused onto the CRD (5, 7, 8).
Therapeutics Inc (NASDAQ: GALT) has appointed Dr Harold H.
family members are molecules increasingly focused upon as regulators of cellular processes including metabolism and inflammation.
lattices regulate lateral mobility of integrins (34), junctional stability of N-cadherins (32), receptor distribution at the cell surface (35), turnover of endocytic receptors (33), and intracellular signaling pathways (31,36-38).
expression in cancer diagnosis and prognosis: A systematic review.
Discovery and characterization of an epithelial-specific galectin
in the endometrium that forms crystals in the trophectoderm.
1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer.